Memorial Sloan Kettering establishes MSKCC India

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Memorial Sloan Kettering Cancer Center has established MSKCC India to provide cancer patients in India with access to the institution’s oncologists, research, clinical trials, and education. 

MSKCC India will provide remote opinions via video or written consultations. A Memorial Sloan Kettering Cancer Center oncologist who specializes in a patient’s form of cancer will review their medical records, test results, and other materials and provide a comprehensive written opinion, meet with the patient virtually using telemedicine technology, or speak with the patient’s local oncologist about their diagnosis and care plan. 

In some cases, they may recommend that the patient travel to receive care at Memorial Sloan Kettering Cancer Center in New York City. Specific services include:

  • Pathology diagnosis
  • Radiology scan reviews
  • Next-generation sequencing (MSK-IMPACTTM) of a patient’s tumor and treatment recommendations
  • Travel assistance to New York City

Memorial Sloan Kettering Cancer Center has partnered with iCliniq, a global telemedicine provider based in India. 

MSKCC India will open a physical location in Chennai, centrally located for patients and staff members. This location will serve as a hub for medical staff who will help patients coordinate written or virtual consultations, and they will be able to communicate in English, Hindi, Urdu, Tamil, Telugu and Kannada. 

If necessary, employees will be able to collect medical records from patients’ homes, making the process more convenient for those utilizing this service. Patients across India will be able to obtain a remote opinion from experts at Memorial Sloan Kettering Cancer Center in the comfort of their home or any internet-enabled location without traveling to MSKCC India in Chennai.

Patients in India now can visit to learn more about MSKCC India and how to schedule a consultation with a Memorial Sloan Kettering Cancer Center expert.

Table of Contents


President Joe Biden has announced his intent to appoint Monica Bertagnolli as the 16th director of the National Cancer Institute—and the first woman and first chair of a clinical trials cooperative group to be named to the role.The White House announcement Aug. 10 comes nearly three weeks after news of Bertagnolli’s appointment leaked out on Twitter and in the press (The Cancer Letter, July 21, 2022).
Can you imagine, as a radiation oncologist, you have to shelter your patients in a Co-60 vault to protect them from missiles, provide them with water by melting snow, feed them, keep them warm by using a backup power generator, and evacuate them just two hours before the missile destroys the radiation oncology department? 
Research shows that cancer patients who receive navigation have improved survival, access to advanced care like clinical trials, and services like genetic testing and palliative care. Navigation often results in increased screening and patients receiving treatment sooner, resulting in improved quality of life and more cancer-free days.